small nuclear ribonucleoprotein polypeptide C pseudogene 2Genealiases: []
Q-omics provides the consensus-scored SNRPCP2 profile across patient tissues and cancer cell-line models. SNRPCP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNRPCP2 is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, SNRPCP2 RNA expression shows 10,997 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, UCEC, and TGCT as cancer lineages where SNRPCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP2 survival associations across molecular data types. SNRPCP2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP2 RNA expression–survival associations across cancer types. High SNRPCP2 expression shows unfavorable associations in ACC and SARC, but favorable associations in OV, HNSC, LUAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for SNRPCP2 RNA expression.
This table summarizes SNRPCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP2 shows higher tumor expression in UCEC, COAD, LUAD, HNSC, LUSC and LIHC. The UCEC box plot shows higher SNRPCP2 RNA expression in tumor versus normal tissue (log2 FC = +0.379, t-test p = .021).
This table shows molecular features associated with SNRPCP2 in patient tissues and cancer cell lines. In patient samples, SNRPCP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
